Vigil Neuroscience (VIGL) reported positive data from completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimers disease. The company said, collectively, the safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral therapy for AD.
Based on the Phase 1 results and preclinical profile of VG-3927, the company plans to advance a once-daily oral dose of 25mg that fully engages the desired pharmacology and expects to begin the Phase 2 trial in the third quarter of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.